Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 10/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 9/20 | 0.40 |
| ▸ | TP53BP1 | Q12888 | 3/20 | 0.39 |
| ▸ | MBTD1 | Q05BQ5 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | ACACA | Q13085 | 1/20 | 0.36 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4519590 | 0.93 | NR1H4 (0.38) | L3MBTL3L3MBTL1ALDH1A1NR1H4ACACB | |
| SCHEMBL4520698 | 0.92 | NR1H4 (0.40) | NR1H4 | |
| SCHEMBL4527486 | 0.91 | NR1H4 (0.40) | ALDH1A1NR1H4 | |
| SCHEMBL4528963 | 0.91 | PRKCB (0.38) | ALDH1A1NR1H4CHRM1 | |
| SCHEMBL4523445 | 0.86 | NR1H4 (0.41) | NR1H4 | |
| SCHEMBL4528374 | 0.86 | NR1H4 (0.38) | NR1H4 | |
| SCHEMBL4525870 | 0.85 | NR1H4 (0.43) | ALDH1A1NR1H4 | |
| SCHEMBL4523812 | 0.85 | HRH4 (0.42) | NR1H4 | |
| SCHEMBL4536855 | 0.84 | NR1H4 (0.36) | ALDH1A1NR1H4 | |
| SCHEMBL4526606 | 0.84 | NR1H4 (0.38) | ALDH1A1NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203577-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203577-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | NR1H4, NR1I2, GPBAR1 | L3MBTL3 4884/4885L3MBTL1 4882/4885TP53BP1 3575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.